Researchers from Model Medicines Inc. have presented preclinical efficacy data for MDL-001, a first-in-class, oral non-nucleoside inhibitor that targets an allosteric site in the Thumb-1 domain of the viral polymerase.
Researchers at Ehime University, Hamamatsu University School of Medicine and Shizuoka University have disclosed compounds reported to be useful for the treatment of hepatitis C virus (HCV) infections.
The Institute of Physical and Chemical Research and Kyoto University have synthesized isoindoline compounds reported to be useful for the treatment of viral infections.
The U.S. foreign aid cuts and freezes that are taking place under President Donald Trump are putting at risk the global public health gains that have been made against diseases such as malaria, HIV and tuberculosis over the past two decades, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said at a March 17 media briefing, as he called on other countries to step up and fill the gap.
Nanjing Sanhome Pharmaceutical Co. Ltd.’s Shengnuodi (alfosbuvir tablets), used as part of a combination treatment for hepatitis C, has been approved by China’s National Medical Products Administration (NMPA) through the priority review and approval procedure.
Nanjing Sanhome Pharmaceutical Co. Ltd.’s Shengnuodi (alfosbuvir tablets), used as part of a combination treatment for hepatitis C, has been approved by China’s National Medical Products Administration (NMPA) through the priority review and approval procedure.
The U.S. Court of Appeals for the Federal Circuit once again delved into genus claims as it affirmed Gilead Sciences Inc.’s win in its inter partes review (IPR) challenge of several claims in a patent held by the University of Minnesota.
The hepatitis C virus (HCV) is so common that it infects approximately 0.7% of the world population to ultimately cause ~300,000 deaths each year. Small molecule-based antivirals can cure most HCV infections, but these are often only used after irreversible liver damage has already occurred, prohibitively expensive, and inaccessible for high-risk populations.
Astrivax BV has raised €30 million (US$30.1 million) in a seed round to take forward the development of a novel vaccine technology that combines a plasmid vector with a replication-competent virus.
The FDA has issued new risk classification orders for two series of products, including in vitro diagnostics for hepatitis C, two of which the agency down-regulated from class III to class II. However, blood lancets for multiple uses on more than one patient has been elevated from class I to class III, a change that has no impact on any products currently available on the U.S. market.
